Abstract
Effects of Glucose Lowering Drugs on Cardiovascular Risk in Type 2 Diabetes Mellitus: Realities and Perspectives
Highlights
A. et al Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise
in type 2 diabetes inadequately controlled with metformin
Duran-Garcia S. et al Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes
Summary
За последние 3 года опубликованы результаты 3 плацебо-контролируемых клинических исследований III фазы по изучению сердечно-сосудистой безопасности аналогов ГПП-1 и агонистов рецепторов ГПП-1 – ликсисенатида [29], лираглутида [30] и семаглутида [31]. В исследовании SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes) у пациентов с СД 2‐го типа и высоким риском развития ССЗ семаглутид также превзошел плацебо по влиянию на первичную комбинированную точку (сердечно-сосудистая смертность, нефатальные ИМ и инсульты; ОР 0,74 при 95 % ДИ от 0,58 до 0,95; р
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
